Article
The role of zongertinib, a highly selective tyrosine kinase inhibitor, in targeting HER2-mutant NSCLC: a bench-to-bedside review.
Expert review of anticancer therapy - 1 Jul 2026
Heymach John V, Popat Sanjay, Smit Egbert F, Christopoulos Petros, Planchard David, Yoshida Tatsuya, Zugazagoitia Jon, Yu Yan, Wilding Birgit
Abstract excerpt
INTRODUCTION: HER2 is mutated in 2-4% of non-small cell lung cancers (NSCLC) and is associated with poor prognosis. Tyrosine kinase inhibitors (TKIs) targeting HER2 have historically been hampered by insufficient efficacy against exon 20 insertion mutations and lack of specificity, resulting in off-target adverse events. Zongertinib is an oral, irreversible HER2-selective TKI that spares wild-type EGFR, thereby...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.